Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

The Zacks Analyst Blog Highlights: IBM, Allergan, Chubb, DISH Network And HP

Published 02/26/2017, 09:30 PM
Updated 07/09/2023, 06:31 AM

For Immediate Release

Chicago, IL – February 27, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM (NYSE: IBM Free Report ), Allergan (NYSE:AGN) (NYSE: AGN Free Report ), Chubb (NYSE:CB) (NYSE: CB Free Report ), DISH Network (NASDAQ: DISH Free Report ) and HP Inc. (NYSE: HPQ Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Monday: IBM, AGN, CB

Today's Research Daily features new research reports on 16 major stocks, including IBM (NYSE: IBM Free Report ), Allergan (NYSE: AGN Free Report ) and Chubb (NYSE: CB Free Report ).

IBM shares have turned around over the last one year (up +35.1% vs. +22.6% for the Zacks Technology sector) on greater appreciation for the company's outlook. The Zacks analyst likes IBM's strategic growth initiatives, including its Big Data & business analytics, cloud computing, mobile and social business. The recent better than expected Q4 earnings report has helped sentiment as well.

The company's cloud-based products continue to win customers like Chubb. In addition, tuck-in acquisitions will lead to incremental revenues, strengthening its technology leadership and resulting in a more favorable mix of business. (You can read the full research report on IBM here . )

Allergan shares have gained +28.6% over the last three months, outperforming the Zacks Medical-Generic Drugs industry, which has increased +10.9% over the same period. Allergan reported strong fourth-quarter results, wherein both earnings and sales beat estimates. Also, the company’s 2017 sales outlook was above expectations. The Zacks analyst likes products like Botox and Linzess as well as new products, which are supporting sales growth.

With the closing of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. However, Allergan faces generic threats for legacy brands like Namenda IR/XR and Asacol HD. (You can read the full research report on Allergan here. )

Chubb shares have outperformed the Zacks Property, Casualty and Title industry over the last three months, gaining +9.8% vs. 7.4%. Chubb’s fourth-quarter earnings outperformed expectations and also improved year over year on higher net premiums written and investment income. Its inorganic growth story seems impressive and should help it achieve higher long-term ROE.

A strong capital position helps Chubb to engage in shareholder friendly moves and invest in strategic initiatives that drive growth. However, the company’s exposure to cat loss and escalating expenses are headwinds. The recent uptrend in long-term interest rates is beneficial to Chubb and others in its space. (You can read the full research report on Chubb here. )

Other noteworthy reports we are featuring today include DISH Network (NASDAQ: DISH Free Report ) and HP Inc. (NYSE: HPQ Free Report ).

Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on IBM – FREE

Get the full Report on AGN – FREE

Get the full Report on CB – FREE

Get the full Report on DISH – FREE

Get the full Report on HPQ – FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



International Business Machines Corporation (NYSE:IBM): Free Stock Analysis Report

Allergan PLC. (AGN): Free Stock Analysis Report

D/B/A Chubb Limited New (CB): Free Stock Analysis Report

DISH Network Corporation (NASDAQ:DISH): Free Stock Analysis Report

HP Inc. (HPQ): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.